RxDoctor Payments Data

Dawn Floyd, NP

Nurse Practitioner · Tifton, GANPI 1346539533

Payments from drug & device makers

$4,246in general payments, 2019–2025

Across 197 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$867
  • Novo Nordisk$659
  • GSK$594
  • Pfizer$320
  • Lilly USA, LLC$267
  • Astellas Pharma US Inc$259
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$3358%
  • Food & beverage$3,91292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,246 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$11,649
Medicare patients
131
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$93,702
MounjaroTirzepatide47$73,415
RybelsusSemaglutide25$35,557
EliquisApixaban51$33,987
FarxigaDapagliflozin Propanediol36$28,987
LinzessLinaclotide26$25,138
JardianceEmpagliflozin17$21,158
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,990
JanuviaSitagliptin Phosphate26$20,688
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$19,389
TrulicityDulaglutide17$18,508
XareltoRivaroxaban14$11,394
Breo ElliptaFluticasone/Vilanterol13$8,636
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,618
Omeprazole178$2,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$659$129,259106 claims
Lilly USA, LLCMounjaro, Trulicity$267$91,92364 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$594$49,01571 claims
PfizerEliquis$320$33,98751 claims
AstraZenecaFarxiga$33$28,98736 claims
AbbVieLinzess, Synthroid$200$27,43946 claims
Boehringer IngelheimJardiance$19$21,15817 claims
Almatica Pharma LLCSertraline Hcl$21$1,651106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Tifton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →